346results about "Spray delivery" patented technology

The invention includes methods of preventing or treating acute lung injury using a MAP3K2 / MAP3K3 inhibitor. The invention further comprises compositions, and kits comprising compositions useful within the invention.

Preparation of cannabinoid formulations containing: Δ9-tetrahydrocannabinol (Δ9-THC), Δ8-tetrahydrocannabinol (Δ8-THC), Δ9-tetrahydrocannabinolic acid (THCa), cannabidiol (CBD), cannabidiolic acid (CBDa), cannabigero (CBG), cannabichromene (CBC) and cannabinol (CBN), either alone or in combinations henceforth known as cannabis, have been created using an emulsification process to encapsulate cannabinoids. The aqueous-based method involves micellular encapsulation of cannabinoids, a method that has been used to increase the bioavailability of poorly permeable, lipophilic drugs. The present invention demonstrates the viability of transdermal delivery with gels and patches for consistent and sustained cannabinoid dosing.

Disclosed herein are kits and methods for treating pulmonary arterial hypertension (PAH), comprising administering to a subject in need thereof: •a therapeutically effective amount of a tyrosine kinase inhibitor or a pharmaceutically acceptable salt thereof; and•a therapeutically effective amount of a dimeric fusion protein comprising: •the extracellular domain of the activin type 2A (ACTR IIA) or the activin type 2B receptor (ACTR IIB); and the Fc domain of human immunoglobulin G1 (IgG1). In some embodiments, the tyrosine kinase inhibitor is Seralutinib or a pharmaceutically acceptable salt thereof and the fusion protein is Sotatercept.

The present invention relates to a process for producing a sterile liquid pharmaceutical composition suitable for administration by inhalation comprising ensifentrine particles, the process comprising: (a) heating the ensifentrine particles at a temperature of from 100° C. to 220° C. to obtain sterile ensifentrine particles; and (b) combining the sterile ensifentrine particles with a sterile liquid vehicle to produce a sterile liquid pharmaceutical composition suitable for administration by inhalation. A process for producing an ampule comprising the sterile liquid pharmaceutical composition is also described.

To provide compositions and methods for regulating protein production in target cells. [Solution] The compositions and methods disclosed herein can improve diseases associated with protein or enzyme deficiency. The present invention provides, for example, a composition comprising (a) at least one mRNA molecule that is at least partly encoding a functionally secreted polypeptide, and (b) a transport vehicle comprising lipid nanoparticles. The present invention also provides a method for treating a subject deficient in a functional polypeptide, comprising administering a composition comprising (a) at least one mRNA that is at least partly encoding the functionally secreted polypeptide, and (b) a transport vehicle comprising lipid nanoparticles, wherein after administration of the composition, the mRNA is expressed in a target cell to produce the functionally secreted polypeptide.

Provided are compositions and drug delivery systems containing extracellular vesicles from microalgae (MEVs) that are loaded with bioactive cargo. The MEVs are formulated and administered by a variety of routes of administration and have a variety of applications as therapeutics, including as vaccines, as anti-cancer therapeutics, as therapeutics for psychiatric diseases, disorders, and conditions as diagnostics, and other such uses.

The present disclosure relates to toxin-derived delivery constructs, in particular isolated non-naturally occurring delivery constructs, for oral delivery, comprising a bacterial toxin-derived delivery construct coupled to a biologically active therapeutic cargo; wherein the delivery construct is capable of delivering a bioactive cargo through epithelial cells via endocytotic transport; and wherein the delivery construct does not comprise a bacterial toxin-derived translocation domain or a bacterial toxin-derived catalytic (cytotoxic) domain.

The present application belongs to the technical field of pharmaceutical preparation, and relates to an electrolytic silver ion solution capable of completely inactivating HIV and a preparation method thereof. The electrolytic silver ion solution uses ultrapure water as a solvent, and contains divalent silver ions, a complexing agent and a complexing agent in the electrolytic silver ion solution. The complexing agent is hexamethylenetetramine capable of forming a stable complex with silver ions and capable of quantitatively analyzing the concentration of silver ions. The hexamethylenetetramine is of an analytical purity grade. The complexing agent is ethylenediamine capable of forming a more stable silver-ammonia complex ion, i.e., diammine silver, and capable of doubling the concentration of the generated silver-ammonia complex ion. The concentration of the divalent silver ions is 200-300 mg.kg ‑1 -1; the highest concentration of the complexing agent is 0.9 g.kg ‑1 -1; and the highest concentration of the complexing agent is 0.55 g.kg ‑1 The complexing agent and the complexing agent of the present application have a small dosage, a high relative ratio of silver ions and a stronger activity, and the inactivation rate of HIV is as high as 99.993%.

The invention provides a lung tissue sustained and controlled release material loaded with BMP4 and GANT61 and a preparation method of the lung tissue sustained and controlled release material, and relates to the technical field of disease treatment and delivery materials. The invention relates to a preparation method of a lung tissue sustained and controlled release material loaded with BMP4 and GANT61. The preparation method comprises the following steps: synthesizing HPG by adopting an anionic ring-opening polymerization method; the preparation method comprises the following steps: mixing HPG with PLA, and reacting to prepare a copolymer PLA-HPG; the copolymer PLA-HPG and GANT61 are blended and subjected to a reaction, and nano particles loaded with GANT61 are prepared; and the GANT61-loaded nano particles and BMP4 are subjected to a mixed reaction, such that the BMP4 and GANT61-loaded lung tissue sustained and controlled release material is prepared. The invention constructs a lung tissue sustained and controlled release material loaded with BMP4 and GANT61, and verifies that the lung tissue sustained and controlled release material can realize an anti-pulmonary fibrosis treatment strategy by inducing alpha-SMA + myofibroblast transdifferentiation, resisting inflammation, resisting oxidation and other multiple targets.

There are disclosed psychedelic and entactogen compounds, the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor, pharmaceutical compositions such as tablet compositions and kits containing the compounds, methods of delivering the compounds in a mist via inhalation, and methods of treating diseases or disorders associated with a serotonin 5-HT2 receptor, such as central nervous system (CNS) disorders or psychological disorders with the compounds of the invention.

Disclosed are compositions for the oral or nasal cavity. The compositions comprise a biologically active agent, a matrix forming agent comprising beta-glucan, and a bulking agent. The compositions can also comprise additional excipients, such as antioxidants, preservatives, taste or flavor enhancers, pH adjusting agents, plasticizers, and sweeteners. Also disclosed are methods of manufacturing the compositions.

Disclosed herein are methods, compounds, and compositions for treating or preventing an inflammasome-mediated disease or condition, including an inflammasome-mediated pulmonary disease or condition.

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof:which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

The invention relates to an application of genipin-1-beta-D gentiobioside in preparation of a medicine for treating chronic obstructive pulmonary disease. The genipin-1-beta-D gentiobioside is prepared into an aerosol inhalation solution, and the aerosol inhalation administration mode is adopted, so that the lung function in the chronic obstructive pulmonary disease can be improved, the content of inflammatory factors in lung tissues can be reduced, and the lung tissue injury can be relieved.

Aspects of the present disclosure include a composition of nafamostat or a pharmaceutically acceptable salt thereof that provides for controlled release of nafamostat or pharmaceutically acceptable salt thereof to a subject for an extended period of time. Compositions according to certain embodiments include a plurality of controlled release beads where each bead includes a core, an active agent layer having nafamostat or a pharmaceutically acceptable salt thereof and a controlled release layer having one or more polymers formulated in an amount sufficient to provide for controlled release of the nafamostat or pharmaceutically 10 acceptable salt thereof. Methods for administering (e.g., orally) the controlled release nafamostat compositions to a subject are also described.

The invention discloses mizoribine for treating cerebral arterial thrombosis. It is found for the first time that mizoribine can reduce the cerebral apoplexy infarction area, inhibit immune cell infiltration of the brain, relieve inflammation of the cerebral parenchyma stroke part, improve damage to the nervous system of the stroke part and promote recovery of the damaged nerve function.

The invention relates to an application of an MYOF protein in preparation of a product for preventing, relieving and / or treating acute lung injury. According to the application, the MYOF protein can be combined with GSDMD-NT, and up-regulation of expression of the MYOF protein can effectively inhibit activation of GSDMD and pyroptosis mediated by GSDMD, so that the MYOF protein has an application prospect in preparation of products for preventing, relieving and / or treating acute lung injury, and the technical problem that alveolar epithelial barriers are easily damaged during treatment can be solved.

The present invention relates to a compounds of general formula (I) inhibiting the JAK family of non-receptor tyrosine protein kinases (JAK1, JAK2, JAK3, and TYK2); methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of the JAK family non-receptor kinases; in particular for the treatment of various inflammatory disease including asthma, COPD and other respiratory diseases.

To provide novel compositions, etc. [Solution] The composition contains l-menthol and at least one component (X) selected from at least one selected from dicarboxylic acid esters, diol esters, monocarboxylic acid esters, esters of polyols having 3 or more hydroxyl groups, esters of polycarboxylic acids having 3 or more carboxyl groups, polyol ethers, polyamines, and alcohols having 6 or more carbon atoms.

There is provided an inhalation device for delivering a deliverable agent in the form of an aerosol or vapor to a user. The device comprises a solid, porous carrier material having a defined porosity, and a deliverable agent located within the pores of the carrier material. The device is operable to heat the carrier material and vaporize the deliverable agent. Deliverable agents that may be delivered to the user include nicotine. Suitable materials for the porous carrier material include chemically bonded ceramic materials and geopolymeric materials.

The present invention discloses compounds of general formula I for use in the treatment and prevention of COVID-19 in human subjects, in particular for inhibiting SARS-CoV-2: [Formula 1] JPEG2024514770000008.jpg5390 (wherein R1 to R6 are the same or different and are H, OH-, or OR7, R7 is a C1 to C3 alkyl group or a C1 to C4 acyl group, with the proviso that at least four of R1 to R6 are other than H).

The present invention provides chimeric klebicins by combining translocation, receptor-binding, and bactericidal domains originated from different klebicins to achieve improved target cell range and bactericidal activity. Also provided are related compositions, kits, and methods of use of these chimeric klebicins.

The invention discloses 3, 3', 4, 4', 5, 5' -hexahydroxy-trans-stilbene or a pharmaceutically acceptable ester thereof, for use in the treatment and prevention of infections with influenza virus in a human subject, especially for inhibiting human influenza virus.

Described are methods for maintaining or improving activity levels in patients lung-related conditions.

The application discloses a preparation method of a novel inhalable anthrax component vaccine based on a mutant strain of anthrax bacillus, and relates to the technical field of immunology medicine. The application provides a mutant strain of anthrax bacillus, and a mutant strain A16R-5.1 with six extracellular protease activity related genes deleted. The vaccine is extracted from the culture supernatant of anthrax prepared by using the mutant strain A16R-5.1, and can induce strong humoral, cellular and mucosal immune responses after immunization, can resist the invasion of anthrax spores, and can neutralize anthrax toxin in an in-vitro experiment.

The invention belongs to the technical field of biological medicines, and particularly relates to a honeysuckle total extract inhalation solution as well as a preparation method and application thereof. According to the invention, the honeysuckle total extract with poor water solubility, phospholipid and chitosan are innovatively and directionally assembled into the chitosan-phospholipid nanoparticles with uniform structure, and the nanoparticles are prepared by adopting a microfluidic technology. The strategy significantly improves the water solubility and stability of the honeysuckle total extract, and successfully prepares an inhalation solution suitable for pulmonary administration based on the nanoparticle dispersion system. The obtained preparation has the characteristics of high physical stability and good bioavailability potential. The honeysuckle total extract inhalation solution provided by the invention can effectively relieve the pathological process of the pyotoxic pneumonia through multiple mechanisms of remarkably inhibiting lung inflammatory response, relieving pulmonary edema, protecting the structural integrity of pulmonary alveoli and the like. Especially, a high-dose group shows a curative effect superior to that of a positive control drug, and a good dose-effect relationship is combined, so that the preparation has remarkable development potential and clinical transformation prospect in treatment of the septic pneumonia.

To provide antibiotic combination therapies for treating an A. baumannii infection in a subject.SOLUTION: Provided are combination therapies comprising rifabutin and a second antibiotic (for example, colistin and cefiderocol). The combinations of antibiotics display synergy to a wide range of A. baumannii strains, the synergy greatly increasing the susceptibility of A. baumannii cells to rifabutin and colistin, with some strains displaying over a 500-fold increase in sensitivity to one of those antibiotics used in combination with the other compared to when that antibiotic is used by itself.SELECTED DRAWING: None

To provide methods and compositions that can potentiate the function of stem cell therapies.SOLUTION: An aspect of the present disclosure provides a method for potentiating function of a stem cell in a subject, comprising the steps of (a) administering to said subject said stem cell; (b) administering to said subject a pharmaceutical composition comprising an encapsulated cannabinoid compound. Here, the step (b) takes place prior to, concurrent with, or subsequent to the step (a). In some embodiments, the step (b) further comprises at least one terpene compound. In some embodiments, the treatment with the step (b) reduces the side effects usually associated with the step (a). In some embodiments, the steps (a) and (b) exhibit a synergetic effect on a process in the subject.SELECTED DRAWING: None

A method of treating a pulmonary condition in a subject having or at risk of having the pulmonary condition generally includes administering to the subject a therapeutic composition in an amount effective to treat the pulmonary' condition. Generally, the therapeutic composition includes purified exosome product (PEP) exosomes and a pharmaceutically acceptable carrier. In one or more embodiments, the PEP exosomes are modified to include at least one exogenous active agent. In one or more embodiments, the therapeutic composition is formulated for delivery directly to a potion of tire pulmonary tract.